RxDoctor Payments Data

Patricia Galanti, MD

Family Medicine · Morgantown, WVNPI 1376629477

Payments from drug & device makers

$791in general payments, 2019–2025

Across 19 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$479
  • Madrigal Pharmaceuticals$105
  • Vivus LLC$79
  • Astellas Pharma US Inc$42
  • AbbVie$21
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$17
  • plus $48 from 4 others

What the payments were for

  • Food & beverage$791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791 in reported general payments places this provider in the 65th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$13,684
Medicare patients
82
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$65,022
MounjaroTirzepatide14$14,542
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,208
Rosuvastatin Calcium99$1,334
Atorvastatin Calcium189$1,076
Bupropion XlBupropion Hcl26$839
Levothyroxine Sodium135$812
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic15$767
Duloxetine Hcl39$606
Metformin Hcl ErMetformin Hcl56$539
Alendronate Sodium57$513
Escitalopram Oxalate42$474
Metoprolol Succinate31$468
Omeprazole23$455
Venlafaxine Hcl ErVenlafaxine Hcl37$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$479$65,02259 claims
Lilly USA, LLCMounjaro$13$14,54214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →